{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T12:06:54Z","timestamp":1781093214747,"version":"3.54.1"},"reference-count":10,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Anais Brasileiros de Dermatologia"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.abd.2026.501353","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T08:58:19Z","timestamp":1776848299000},"page":"501353","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Predictors of early high-level response to bimekizumab in patients with moderate-to-severe plaque psoriasis: a real-world cohort study"],"prefix":"10.1016","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5140-1926","authenticated-orcid":false,"given":"Burhan","family":"Engin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuf","family":"Demir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurbuz","family":"Yildirim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatma Zehra","family":"Diken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bengusu","family":"Yildiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zekayi","family":"Kutlubay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Server","family":"Serdaroglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.abd.2026.501353_bib0005","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa2102383","article-title":"Bimekizumab versus secukinumab in Plaque Psoriasis","volume":"385","author":"Reich","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.abd.2026.501353_bib0010","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa2102388","article-title":"Bimekizumab versus adalimumab in Plaque Psoriasis","volume":"385","author":"Warren","year":"2021","journal-title":"N Engl J Med."},{"key":"10.1016\/j.abd.2026.501353_bib0015","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0140-6736(21)00126-4","article-title":"Bimekizumab efficacy and safety in moderate to severe Plaque Psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial","volume":"397","author":"Gordon","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.abd.2026.501353_bib0020","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/jid.2009.59","article-title":"The IL-23\/Th17 axis in the immunopathogenesis of psoriasis","volume":"129","author":"Di Cesare","year":"2009","journal-title":"J Invest Dermatol."},{"key":"10.1016\/j.abd.2026.501353_bib0025","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1136\/annrheumdis-2017-212127","article-title":"Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation","volume":"77","author":"Glatt","year":"2018","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.abd.2026.501353_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.abd.2025.501132","article-title":"Predictors of PASI90 response in patients with psoriasis treated with interleukin inhibitors: observational cohort study","volume":"100","author":"Engin","year":"2025","journal-title":"An Bras Dermatol."},{"key":"10.1016\/j.abd.2026.501353_bib0035","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40259-017-0231-8","article-title":"Immunogenicity of biologics in chronic \u0131nflammatory diseases: a systematic review","volume":"31","author":"Strand","year":"2017","journal-title":"BioDrugs."},{"key":"10.1016\/j.abd.2026.501353_bib0040","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1111\/jdv.16521","article-title":"Efficacy of risankizumab in patients with moderate-to-severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa-1 and UltIMMa-2 studies","volume":"34","author":"Strober","year":"2020","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.abd.2026.501353_bib0045","first-page":"51","article-title":"Nail psoriasis: clinical features, pathogenesis, differential diagnoses, and management","volume":"7","author":"Haneke","year":"2017","journal-title":"Psoriasis (Auckl)."},{"key":"10.1016\/j.abd.2026.501353_bib0050","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1007\/s13555-024-01295-w","article-title":"Bimekizumab efficacy in high-\u0131mpact areas: pooled 2-year analysis in scalp, nail, and palmoplantar Psoriasis from phase 3\/3b randomized controlled trials","volume":"14","author":"Merola","year":"2024","journal-title":"Dermatol Ther."}],"container-title":["Anais Brasileiros de Dermatologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0365059626000668?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0365059626000668?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T11:41:27Z","timestamp":1781091687000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0365059626000668"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0365059626000668"],"URL":"https:\/\/doi.org\/10.1016\/j.abd.2026.501353","relation":{},"ISSN":["0365-0596"],"issn-type":[{"value":"0365-0596","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictors of early high-level response to bimekizumab in patients with moderate-to-severe plaque psoriasis: a real-world cohort study","name":"articletitle","label":"Article Title"},{"value":"Anais Brasileiros de Dermatologia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.abd.2026.501353","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Sociedade Brasileira de Dermatologia. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"501353"}}